Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Acute Myeloid Leukemia NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncolyze, Inc, a biotech developing a disruptive technology for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA)...